Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden proposes Medicaid, Medicare cover ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...

Ozempic, Wegovy, and other weight-loss drugs could make millions healthier, but access and affordability barriers abound.